Regulatory Jobs

The BIOSECURE Act Is Pushing Biotech Manufacturing Away From Chinese CDMOs

The BIOSECURE Act isn't law yet, but it's already pushing biotech manufacturing away from named Chinese CDMOs, driving demand for tech transfer and CMC talent.

Connor Griggs

Connor GriggsMSRACQA

Founder & Editor-in-Chief

7 min read

Introduction

A piece of pending US federal legislation most patients have never heard of is already reshaping where biotech and pharma companies choose to manufacture their products, and with it, where a meaningful slice of CMC, quality and supply chain hiring is happening. The BIOSECURE Act targets a short list of named Chinese biotechnology and genomics companies, restricting federal contracts and federal funding for organizations that rely on them. It has not been signed into law as of this writing, and its exact path through Congress has been anything but straight. But the commercial behavior it has already triggered — sponsors and CDMOs moving manufacturing and sequencing work away from the named companies well ahead of any legal requirement to do so — is real, and it is creating its own distinct hiring pattern worth understanding whether or not the bill ultimately passes.

What the BIOSECURE Act Actually Does

As introduced, the bill would bar US federal agencies from contracting with, or from providing federal funding to, biotechnology companies that use "biotechnology equipment or services" from a specific list of named Chinese companies — most prominently WuXi AppTec and WuXi Biologics, along with BGI Group, MGI, and Complete Genomics. Because WuXi AppTec and WuXi Biologics are among the largest contract development and manufacturing organizations (CDMOs) in the world, serving a large share of the US and European biopharma industry for everything from early-stage process development to commercial-scale biologics manufacturing, a restriction aimed at federal contractors has implications that ripple well beyond companies that sell directly to the US government. The bill as drafted has included a multi-year transition window for companies with existing contracts, recognizing that unwinding an active manufacturing relationship takes real time.

Where the Bill Actually Stands

Since its introduction in 2024, the BIOSECURE Act has moved further than most bills that never become law: it cleared a House committee vote with notable bipartisan support and was, at one point, folded into a broader must-pass legislative vehicle before being stripped back out before final passage. As of this writing it remains pending rather than enacted, and its backers have continued reintroducing or attaching it to other legislation across subsequent sessions of Congress. Readers tracking this directly should check its current status before assuming either that it has passed or that it is dead — legislation like this tends to move in fits and starts rather than a clean up-or-down vote, and treating its eventual outcome as settled in either direction would be premature.

Why Sponsors Are Moving Before the Law Does

What makes this story relevant for hiring regardless of the bill's fate is that much of the industry has stopped waiting to find out. Large pharmaceutical companies increasingly ask prospective CDMO partners to document where manufacturing actually happens and to show a credible plan for geographic diversification. Institutional investors have started asking portfolio companies about exposure to the named Chinese manufacturers as a disclosed risk factor. And several biotech companies that had process development or clinical manufacturing agreements with WuXi entities have publicly announced plans to transition that work to other CDMOs, citing exactly this political and commercial risk rather than waiting for a final legislative outcome. Whether the Act ultimately passes, the behavior it has already triggered, companies hedging against a risk that has not yet materialized into law, is the more durable story for anyone hiring or job hunting in this space.

Who Benefits: The CDMO Buildout Outside China

The practical effect has been a wave of capacity expansion among CDMOs outside China. US-based biomanufacturers, European contract manufacturers, and large Asian players outside China such as Samsung Biologics in South Korea have all announced or accelerated capacity expansions that line up closely with the timeline of the BIOSECURE debate. Some of this is genuinely new capacity; some of it is existing CDMOs absorbing client relationships that would otherwise have gone to the now-politically-exposed Chinese providers. Either way, it adds up to real hiring demand at facilities that did not need nearly as much staff two or three years ago.

The Hiring Demand This Creates

Moving an active manufacturing process from one CDMO to another is not a simple handoff; it is a technical transfer project that can take a year or more and touches several distinct job functions. Technology transfer specialists, who understand both the originating process and the receiving facility well enough to make sure a biologic manufactured in the new location behaves identically to the one made in the old one, are in particularly tight supply. CMC regulatory affairs staff are needed to manage the resulting submissions: a change in manufacturing site typically requires notifying or seeking approval from every regulator where the product is marketed, a substantial undertaking for a product sold in dozens of countries. Quality teams need people to qualify the new manufacturing site and its suppliers from scratch, and supply chain and vendor management roles have grown to handle the due diligence now expected before signing with any CDMO, Chinese or otherwise.

Not a New Pattern, Just a New Target

None of this is unprecedented in life sciences, even if the specific target is new. Pharmaceutical and biotech companies have gone through comparable reshoring and diversification pushes before: the active pharmaceutical ingredient supply chain's heavy concentration in a small number of countries has driven similar discussions for years, and drug shortage prevention rules enacted more recently have pushed companies to document and diversify their API sourcing for much the same reason — overreliance on too few suppliers in too few places creates risk regardless of which country sits on the other end. What distinguishes the BIOSECURE moment is less the underlying logic than the speed and visibility of the response: the political signal is loud enough that companies have started acting on anticipated risk well before the law requiring them to act actually exists, which is unusual even for an industry that does plenty of risk-driven supply chain planning.

What This Means If You Already Work With an Affected CDMO

For regulatory, quality and clinical professionals currently working at or with a company that uses one of the named manufacturers, the practical advice is less dramatic than the politics around it suggests: review existing manufacturing and supply contracts for any clauses tied to political or regulatory risk, understand what a technology transfer to an alternate site would actually require for your specific product and markets, and treat this as one input among several in long-term site strategy rather than a reason for sudden action. Companies that have already started this work describe it as a multi-year undertaking handled through ordinary supply chain risk management processes, not an emergency.

Why Clinical-Stage Companies Are Not Exempt

It is tempting to assume this story only matters for large, commercial-stage pharmaceutical companies with federal contracts to protect, but clinical-stage biotechs are affected too, often earlier in their thinking than people expect. A company planning a pivotal trial and eventual commercial launch has to pick a manufacturing partner years before approval, and the capacity and regulatory lead time involved means that decision gets made with an eye toward where the product will need to be manufactured at commercial scale, not just where the current clinical batches are coming from. Venture investors and larger pharma partners doing diligence on a clinical-stage company's manufacturing plan have increasingly started asking about this directly, which means even early-career CMC and regulatory professionals at smaller companies are likely to run into these questions well before any product they work on is close to market.

Watching This Space

For job seekers and career planners, the more durable lesson may be about which skills this kind of geopolitical supply chain shift rewards regardless of how any single piece of legislation turns out: technology transfer experience that spans multiple manufacturing sites, CMC regulatory fluency across international markets, and quality qualification experience with new suppliers are all skills that stay valuable whether the BIOSECURE Act passes, stalls again, or gets replaced by the next version of the same underlying political pressure. Anyone building a CMC or quality career with an eye toward this kind of work would do well to seek out multi-site or technology transfer experience deliberately, rather than waiting for a single employer to hand it to them.

How to Read a Job Posting Shaped by This Shift

For someone actively job hunting, this trend shows up less as postings that mention the BIOSECURE Act by name and more as a particular flavor of requirement stacking up across CMC, quality and supply chain roles: experience with technology transfer "in" to a new manufacturing site rather than just "out," familiarity with comparability protocols for demonstrating a transferred process matches the original, and site qualification or supplier qualification experience specifically framed around onboarding a new manufacturing partner rather than maintaining an existing one. Postings at CDMOs expanding capacity outside China, and at sponsor companies actively moving programs between manufacturing partners, are worth reading closely for exactly this language, since it is often a more reliable signal of what the role actually involves than the job title itself.

Conclusion

The BIOSECURE Act is, strictly speaking, still just a bill, one that has advanced further than most without yet becoming law. But the manufacturing diversification it has already set in motion is a live hiring story independent of its ultimate legislative fate, and it is a useful reminder that in this industry, political risk that has not yet become binding law can move hiring and capacity decisions almost as much as a regulation that already has.

Regulatory & Quality. REWIRED.

New roles. Real pay. Your next move.

  • Hand-picked roles, every week.
  • The newest company pages.
  • One article worth your time.
Get the Weekly

Free. Thursday mornings. One-click unsubscribe.

Connor GriggsConnor Griggs

About the author

Connor GriggsMSRA, CQA

Founder & Editor-in-Chief

Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.

Find your next regulatory or quality role

Every role on Regulatory Jobs is in regulatory, quality or clinical, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.

Next in News & UpdatesWhat FDA's QMSR Means for Regulatory and Quality Careers in Medical Devices